Altamira Therapeutics Ltd
CYTO
CYTO was delisted on the 19th of December, 2024.
16 hedge funds and large institutions have $1.03M invested in Altamira Therapeutics Ltd in 2021 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 3 closing their positions.
167% more call options, than puts
Call options by funds: $222K | Put options by funds: $83K
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
7% more funds holding
Funds holding: 15 → 16 (+1)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
24% less capital invested
Capital invested by funds: $1.34M → $1.03M (-$316K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$106K |
| 2 |
Group One Trading
Chicago,
Illinois
|
+$83.8K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$31.5K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$17.4K |
| 5 |
Jane Street
New York
|
+$16.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
-$158K |
| 2 |
Renaissance Technologies
New York
|
-$143K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$96.5K |
| 4 |
Two Sigma Investments
New York
|
-$32K |
| 5 |
BFM
Boothbay Fund Management
New York
|
-$16.1K |
CYTO Hedge Fund Activity: Q4 2021 in Review
16 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Altamira Therapeutics Ltd (CYTO) for Q4 2021, worth a combined $1.03M — down 24% from $1.34M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new CYTO positions and 3 closed out — a net gain of 1 holder — while 4 added to existing stakes and 5 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $106K. The largest seller was Ikarian Capital, cutting an estimated $158K.
- 16 institutional investors held Altamira Therapeutics Ltd (CYTO) as of Q4 2021, up from 15 in Q3 2021.
- Funds reported $1.03M of Altamira Therapeutics Ltd stock for Q4 2021, down 24% quarter-over-quarter.
- 4 funds opened new Altamira Therapeutics Ltd positions in Q4 2021 and 3 closed out, a net change of +1 holder.
- The largest Altamira Therapeutics Ltd buyer in Q4 2021 was Susquehanna International Group, an estimated $106K added.
- The largest Altamira Therapeutics Ltd seller in Q4 2021 was Ikarian Capital, an estimated $158K sold.
Based on aggregated 13F filings for Q4 2021.